Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Molecular markers for prostatic cancer.
Castelli T, Cimino S, Magno C, Morgia G. Castelli T, et al. Front Biosci (Elite Ed). 2010 Jan 1;2:641-56. doi: 10.2741/e120. Front Biosci (Elite Ed). 2010. PMID: 20036908 Review.
[Validity of PSA density of the transition zone in the diagnosis of prostate cancer].
Anastasi G, Magno C, Carmignani A, Inferrera A, Petrelli A, Broccio G. Anastasi G, et al. Arch Ital Urol Androl. 2000 Dec;72(4):190-3. Arch Ital Urol Androl. 2000. PMID: 11221034 Italian.
PHI and PCA3 improve the prognostic performance of PRIAS and Epstein criteria in predicting insignificant prostate cancer in men eligible for active surveillance.
Cantiello F, Russo GI, Cicione A, Ferro M, Cimino S, Favilla V, Perdonà S, De Cobelli O, Magno C, Morgia G, Damiano R. Cantiello F, et al. World J Urol. 2016 Apr;34(4):485-93. doi: 10.1007/s00345-015-1643-z. Epub 2015 Jul 21. World J Urol. 2016. PMID: 26194612 Clinical Trial.
Fluorodeoxyglucose positron emission tomography may aid the diagnosis of aggressive primary prostate cancer: A case series study.
Bartoletti R, Meliani E, Bongini A, Magno C, Cai T. Bartoletti R, et al. Oncol Lett. 2014 Feb;7(2):381-386. doi: 10.3892/ol.2013.1747. Epub 2013 Dec 9. Oncol Lett. 2014. PMID: 24396452 Free PMC article.
Transurethral ethanol ablation of the prostate (TEAP): an effective minimally invasive treatment alternative to traditional surgery for symptomatic benign prostatic hyperplasia (BPH) in high-risk comorbidity patients.
Magno C, Mucciardi G, Galì A, Anastasi G, Inferrera A, Morgia G. Magno C, et al. Int Urol Nephrol. 2008;40(4):941-6. doi: 10.1007/s11255-008-9394-z. Epub 2008 May 14. Int Urol Nephrol. 2008. PMID: 18478352
Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia.
Altavilla D, Minutoli L, Polito F, Irrera N, Arena S, Magno C, Rinaldi M, Burnett BP, Squadrito F, Bitto A. Altavilla D, et al. Br J Pharmacol. 2012 Sep;167(1):95-108. doi: 10.1111/j.1476-5381.2012.01969.x. Br J Pharmacol. 2012. PMID: 22471974 Free PMC article.
EXPERIMENTAL APPROACH: Rats were treated daily with testosterone propionate (3 mg·kg(-1)  s.c.) or its vehicle for 14 days to induce BPH. ...
EXPERIMENTAL APPROACH: Rats were treated daily with testosterone propionate (3 mg·kg(-1)  s.c.) or its vehicle for 14 days to induce …
High-Dose Robotic Stereotactic Body Radiotherapy in the Treatment of Patients With Prostate Cancer: Preliminary Results in 26 Patients.
Pontoriero A, Iatì G, Mondello S, Midili F, Siragusa C, Brogna A, Ielo I, Anastasi G, Magno C, Pergolizzi S, De Renzis C. Pontoriero A, et al. Technol Cancer Res Treat. 2016 Feb;15(1):179-85. doi: 10.1177/1533034614566994. Epub 2015 Jan 13. Technol Cancer Res Treat. 2016. PMID: 25586517
Oxidative stress in benign prostatic hyperplasia: a systematic review.
Minciullo PL, Inferrera A, Navarra M, Calapai G, Magno C, Gangemi S. Minciullo PL, et al. Urol Int. 2015;94(3):249-54. doi: 10.1159/000366210. Epub 2014 Dec 5. Urol Int. 2015. PMID: 25503259 Review.
99 results
Jump to page
Feedback